- Home
- SWTX vs HAYW Comparison
SWTX vs HAYW Comparison
Compare SWTX & HAYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- HAYW
- Stock Information
- Founded
- SWTX 2017
- HAYW 1925
- Country
- SWTX United States
- HAYW United States
- Employees
- SWTX N/A
- HAYW N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- HAYW Electronic Components
- Sector
- SWTX Health Care
- HAYW Technology
- Exchange
- SWTX Nasdaq
- HAYW Nasdaq
- Market Cap
- SWTX 3.5B
- HAYW 2.9B
- IPO Year
- SWTX 2019
- HAYW 2021
- Fundamental
- Price
- SWTX $47.00
- HAYW $13.74
- Analyst Decision
- SWTX Buy
- HAYW Hold
- Analyst Count
- SWTX 7
- HAYW 5
- Target Price
- SWTX $56.86
- HAYW $16.83
- AVG Volume (30 Days)
- SWTX 4.5M
- HAYW 1.8M
- Earning Date
- SWTX 08-06-2025
- HAYW 07-29-2025
- Dividend Yield
- SWTX N/A
- HAYW N/A
- EPS Growth
- SWTX N/A
- HAYW 51.32
- EPS
- SWTX N/A
- HAYW 0.56
- Revenue
- SWTX $219,670,000.00
- HAYW $1,067,878,000.00
- Revenue This Year
- SWTX $74.36
- HAYW $5.27
- Revenue Next Year
- SWTX $75.63
- HAYW $5.51
- P/E Ratio
- SWTX N/A
- HAYW $24.67
- Revenue Growth
- SWTX 730.42
- HAYW 7.34
- 52 Week Low
- SWTX $28.21
- HAYW $11.10
- 52 Week High
- SWTX $62.00
- HAYW $16.87
- Technical
- Relative Strength Index (RSI)
- SWTX 63.86
- HAYW 48.98
- Support Level
- SWTX $46.93
- HAYW $13.20
- Resistance Level
- SWTX $47.02
- HAYW $14.02
- Average True Range (ATR)
- SWTX 0.08
- HAYW 0.32
- MACD
- SWTX -0.06
- HAYW -0.03
- Stochastic Oscillator
- SWTX 90.32
- HAYW 48.54
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.